Mar 31, 2022 / 04:00PM GMT
Debjit D. Chattopadhyay - Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Good afternoon, and thank you for joining Guggenheim Genomic Medicines and Rare Disease Conference. I'm Debjit. I'm one of the analysts representing the Guggenheim Therapeutics team. My privilege to host Sarepta's President and CEO; Doug Ingram; and Executive Vice President and CFO, Ian Estepan. Thank you for your time today, gentlemen.
Questions and Answers:
Debjit D. Chattopadhyay - Guggenheim Securities, LLC, Research Division - Senior Analyst of BiotechnologyAnd with that, Doug, let me start with a broad question. 5 years since you started at Sarepta. How do you feel about the progress to date? And if there is anything you could have done differently, what's that?
Douglas S. Ingram - Sarepta Therapeutics, Inc. - President, CEO & Director
I'm sure there's a lot of things I could have done differently. It's interesting, people who know me will say that I am perennially unsatisfied with everything. I
Trustpilot
